Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Novo Nordisk said the Central Drugs Standard Control Organisation (CDSCO) approved Wegovys 2.4 mg semaglutide injection for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), which is a serious form of fatty liver disease
Like all prescription medications, your primary care provider serves as their gatekeeper
For anyone tracking their progress, remember that weight loss is not linear on either medication
Insurance approval processes that take 2-8 weeks delay treatment start, potentially reducing total weight loss outcomes
This matters because muscle supports strength, daily function, glucose control, resting metabolic rate, and long-term weight maintenance
It also has strong antioxidant properties, and through its support for both heart and brain health, encourages healthy aging and whole-body health
US$ 20.66
US$ 24.31
US$ 21.04
US$ 24.30
